Immunotech Biopharm
Beijing, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A biopharma company engineering novel antibody therapeutics, including bispecifics and ADCs, for oncology and immunology.
OncologyImmunology
Technology Platform
Integrated antibody discovery and engineering platforms for developing bispecific antibodies and antibody-drug conjugates (ADCs).
Opportunities
Advancing its novel antibody constructs into later-stage trials for high-value oncology indications with strong biomarker strategies.
Risk Factors
Clinical development risks inherent to novel biologic mechanisms and potential for severe adverse events (e.g., CRS with T-cell engagers).
Competitive Landscape
Faces intense competition in the crowded bispecific and ADC space, requiring clear clinical differentiation to succeed.